Molecular Partners Ag (MLLCF)

$2.25 -0.10 (-4.25%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 400
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting t...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 44 755 77 00
Fax: 41 44 755 77 07
Address:
Wagistrasse 14, Schlieren, Switzerland
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 10:41 PM
$MLLCF Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M at constant exchange rates, including approximately CHF6M in non-cash effective costs.
0 · Reply
Latest News on MLLCF
No data available.
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 10:41 PM
$MLLCF Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M at constant exchange rates, including approximately CHF6M in non-cash effective costs.
0 · Reply